Loading...
Please wait, while we are loading the content...
Similar Documents
Efficacy and safety of non-vitamin K antagonist oral anticoagulants for venous thromboembolism: a meta-analysis
| Content Provider | SAGE Publishing |
|---|---|
| Author | Zhuang, Yan Dai, Lin-feng Chen, Ming-qi |
| Copyright Year | 2021 |
| Abstract | ObjectiveSeveral trials had compared the efficacy and safety between non-vitamin K antagonist oral anticoagulants and warfarin for acute venous thromboembolism, but the results were incomplete. This updated review comprehensively assessed the efficacy and safety of non-vitamin K antagonist oral anticoagulants for venous thromboembolism.DesignMeta-analysis of randomised control trials. Six databases were searched from January 2000 to December 2018.SettingAdult patients had got non-vitamin K antagonist oral anticoagulants or warfarin for venous thromboembolism.ParticipantsRandomised control trials that compared the efficacy and safety between non-vitamin K antagonist oral anticoagulants and warfarin.Main outcome measuresThe efficacy and safety of non-vitamin K antagonist oral anticoagulants .ResultsSeven studies involving 29,879 cases were included, among which 14,943 cases were assigned to non-vitamin K antagonist oral anticoagulants group and 14,936 cases to warfarin group. Meta-analysis showed that compared with warfarin, recurrent venous thromboembolism (odds ratio 0.94 [95% confidence interval 0.81 to 1.11]), death related to venous thromboembolism or fatal pulmonary embolism (odds ratio 1.00 [95% confidence interval 0.63 to 1.60]), symptomatic deep-vein thrombosis (odds ratio 0.88 [95% confidence interval 0.72 to 1.09]), symptomatic nonfatal pulmonary embolism (odds ratio 1.03 [(95% confidence interval 0.82 to 1.30]) and all deaths (odds ratio 0.92 [95% confidence interval 0.76 to 1.12]) are similar in non-vitamin K antagonist oral anticoagulants group, but major bleeding event (odds ratio 0.61 [95% confidence interval 0.50 to 0.75]) and clinically relevant non-major bleeding event (odds ratio [95% confidence interval 0.53 to 0.85]) are less in non-vitamin K antagonist oral anticoagulants group. ConclusionsFor the treatment of venous thromboembolism, non-vitamin K antagonist oral anticoagulants is as effective as warfarin, and has a better safety profile than warfarin. |
| Related Links | https://journals.sagepub.com/doi/pdf/10.1177/20542704211010686?download=true |
| ISSN | 20542704 |
| Issue Number | 6 |
| Volume Number | 12 |
| Journal | JRSM Open (SHR) |
| e-ISSN | 20542704 |
| DOI | 10.1177/20542704211010686 |
| Language | English |
| Publisher | Sage Publications UK |
| Publisher Date | 2021-06-13 |
| Publisher Place | London |
| Access Restriction | Open |
| Rights Holder | © The Author(s) 2021 |
| Subject Keyword | deep-vein thrombosis pulmonary embolism non-vitamin K antagonist oral anticoagulants warfarin randomised control trial Venous thromboembolism |
| Content Type | Text |
| Resource Type | Article |
